| 肿瘤患者静脉血栓栓塞症的一级预防及研究进展 |
| |
| 引用本文： | 马旭,王丹,韩森.肿瘤患者静脉血栓栓塞症的一级预防及研究进展[J].中国肿瘤临床,2020,47(6):309-313. |
| |
| 作者姓名： | 马旭 王丹 韩森 |
| |
| 作者单位： | 北京大学肿瘤医院暨北京市肿瘤防治研究所, 恶性肿瘤发病机制及转化研究教育部重点实验室(北京市 100142) |
| |
| 基金项目： | 北京大学肿瘤医院科学研究基金项目2020自主-27北京市医院管理中心培育计划PG2020023 |
| |
| 摘 要： | 肿瘤相关静脉血栓栓塞症(cancer-associated venous thromboembolism,CAVTE)是肿瘤患者常见的并发症和死亡原因。因此,如何预防CAVTE的发生受到越来越多的关注。预防性抗凝治疗可以降低肿瘤患者的血栓发生风险,因此需要将患者的获益和不良反应进行充分评估,排除抗凝治疗禁忌后,对血栓高危患者进行预防性的抗凝治疗。
|
| 关 键 词： | 肿瘤相关静脉血栓栓塞症 血栓预防 低分子肝素 新型口服抗凝药 肿瘤心脏病学 |
| 收稿时间： | 2020-03-01 |
Primary prevention and research progress of venous thromboembolism in patients with cancer |
| |
| Institution: | Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China |
| |
| Abstract: | Cancer-associated venous thromboembolism (VTE) is a common complication and cause of death in patients with cancer. Therefore, strategies to prevent the occurrence of VTE have increasingly attracted attention. Prophylactic anticoagulant therapy can reduce the risk of VTE in patients with cancer. It is necessary to completely evaluate the benefits and potential adverse reactions and eliminate any contraindications of anticoagulant therapy before prophylactic anticoagulant therapy is administered to high-risk patients. |
| |
| Keywords: | cancer-associated venous thromboembolism thrombosis prevention low molecular weight heparin new oral anticoagulants onco-cardiology |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
